dexamethasone and adriamycin. Results were bad, the median survival was around two years. In the 1990s something good happened; thalidomide …
Developing Hematology is a blog written for medical professionals who practice clinical hematology in developing countries
We aim to offer a practical insight, from the perspective of scientists working in low to middle-income countries, where most of the population of the entire world are actually living in.
Free from the shackles of formality which limit our written word to rigid scientific language in peer reviewed medical journals, this space offers sincere opinions from a variety of editorialists on current clinical hematology research.
With a focus on issues regarding resource optimization, diagnostic strategies and treatment availability, Developing Hematology hopes to become a useful reference for all professionals working in a restricted environment.
dexamethasone and adriamycin. Results were bad, the median survival was around two years. In the 1990s something good happened; thalidomide …
While acute myeloid leukemia (AML) patients have a chance for long-term remission and cure, some of them will not attain …
Mantle cell lymphoma (MCL) is a B-cell malignancy with an inferior prognosis in comparison to other lymphomas. Most patients present …